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Introduction
Carcinoid tumours were first described more than 100 
years ago by Lubarsh.1 The term “carcinoid” means 
“carcinoma like”, and was used to describe tumours 
that had a more indolent behaviour than that which was 
typical of carcinomas. As carcinoid tumours arise from 
neuroendocrine (enterochromaffin) cells, they can occur in 
a wide variety of organs, including the gastrointestinal tract, 
lungs, and ovaries. These rare tumours may go undiagnosed 
for many years, and patients may complain only of vague 
non-specific symptoms. We present two patients, each 
with a metastatic carcinoid tumour, and whose clinical 
presentations were complicated by cardiac involvement.
Case 1
A 57-year-old man presented with a three-year history 
of intermittent watery diarrhoea and frequent episodes 
of nausea and vomiting, unrelated to meals. Repeated 
gastric endoscopies at a secondary care hospital gave a 
normal result. He also complained of a 15 kg weight loss, 
unprovoked episodes of flushing, intense generalised 
pruritus, and ultimately fixed violaceous skin changes on 
his nose and cheeks. He was referred to Groote Schuur 
Hospital with right-sided heart failure and dyspnoea on 
minimal exertion (class III, New York Heart Association). On 
review, he was wasted, exhibited the rash as described, as 
well as telangiectasia of the face, and had right heart failure 
secondary to severe tricuspid regurgitation and a markedly 
enlarged liver, spanning 22 cm with a macronodular surface, 
suggestive of multiple hepatic metastases.  
The urinary 5-hydroxyindoleacetic acid level (5-HIAA) at 
presentation was 820.8 µmol/24 hours (normal = 10.4-41 
µmol/24 hours), whereas liver function tests and clotting 
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Abstract
We present two cases of metastatic carcinoid tumours, complicated by carcinoid syndrome and by cardiac valve involvement, 
a well-known, but infrequent, complication. Carcinoid tumours are generally more indolent than other cancers and may have 
a long asymptomatic phase. The symptoms of carcinoid syndrome generally manifest only once metastases to the liver have 
occurred. Cardiac involvement occurs in up to 50% of patients, and heralds a poor prognosis. However, a multidisciplinary 
team approach has improved the prognosis and quality of life for patients with carcinoid heart disease. Therapy includes 
somatostatin analogues and treatment for heart failure, removal of primary or metastatic tumour deposits, valve replacement 
in the presence of valvular involvement, and radioisotopes therapy. 
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Figure 1: Contrast computed tomography of the abdomen at the level 
of T11 shows the markedly enlarged liver, with coexisting hypoechoic 
nodules, pathognomonic of metastatic disease
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profiles were within normal ranges. Computed tomography 
(CT) of the abdomen confirmed extensive liver metastases 
of varying size (Figure 1). 
An echocardiogram showed thickened and retracted 
tricuspid valve leaflets, resulting in severe tricuspid 
regurgitation and a dilated right ventricle and atrium. 
However, the left ventricle, left atrial dimensions and mitral 
and aortic valves were within normal limits.  Due to the high 
cost of a diagnostic radiolabelled octreotide scan, and lack 
of an octreotide therapeutic option, an Iodine 123 MIBG 
(m-iodobenzylguanidine) scan was obtained. The I123 MIBG 
scan demonstrated multiple sites of abnormal uptake in the 
chest, liver and abdomen (Figure 2). 
His cardiac failure improved with medical therapy, and 
11.1GBq (300 mCi) I131 MIBG was administered. The patient 
died two weeks later. Inferior vena caval obstruction, 
thought to be due to tumour compression, was suggested 
as the cause of death at autopsy. 
Case 2
In 2005, a 39-year-old woman with a confirmed amoebic 
liver abscess was managed at Groote Schuur Hospital 
with drainage and metronidazole. Over the next two years 
she developed intermittent watery diarrhoea and episodic 
facial flushing.  Two years later, a routine follow-up CT scan 
demonstrated a new hypodense lesion within the liver. 
Histology of a plugged liver biopsy was highly suggestive 
of a metastatic carcinoid tumour. This was corroborated 
by markedly elevated urinary 5-HIAA (899 µmol/24 hours) 
and chromogranin A levels [> 585 U/l (normal = 0-23 U/l)]. 
Due to cost constraints, somatostatin receptor agonists 
were not available in our institution. Two years later, she 
developed symptoms of right-sided heart failure with 
features of pulmonary hypertension, together with daily 
watery diarrhoea and a minimum of two to three episodes 
per day of facial and truncal flushing, with each episode 
lasting between 30 minutes to three hours. On examination, 
she showed features of severe pulmonary hypertension and 
right heart failure, attributed to tricuspid regurgitation and 
mixed pulmonary valve disease. Her liver was massively 
enlarged, and exhibited a macronodular surface, suggestive 
of advanced metastatic carcinoid.
Urinary 5-HIAA levels increased to 1 975 µmol/24 hours in 
keeping with increased tumour burden. Repeat CT abdomen 
(Figure 3) suggested an isolated small bowel lesion with 
extensive hepatic metastases.
Figure 3: Double contrast CT scan at level of T10 showing grossly 
enlarged liver with a large hypoechoic lesion in the left lobe, and multiple 
smaller lesions in the right lobe, in keeping with metastatic disease
Figure 2: Whole body I123 MIBG scan demonstrates multiple sites of 
abnormal uptake in the chest, liver and abdomen, indicative of extensive 
metastatic disease 
Figure 4: Whole body I123 MIBG scan showing abnormal uptake in the liver, 
as well as a focus in the mid-abdominal region
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 An I123 MIBG scan (Figure 4) demonstrated abnormal uptake 
in the mid-abdomen and  liver, corresponding  to the lesions 
seen on the abdominal CT scan. Echocardiography revealed 
markedly thickened and abnormal tricuspid leaflets with 
dilated right atrium and ventricle, coexisting with severe 
tricuspid regurgitation. The pulmonary valve appeared 
thickened and poorly mobile, resulting in severe mixed 
pulmonary valve disease, predominantly stenosis, with a 
transvalvular gradient of 40 mmHg. 
Following initial optimisation of her cardiac failure with 
appropriate diuretics, she received a therapeutic dose 
of  I131 MIBG 11.1 GBq (300 mCi). Thereafter, twice daily, 
subcutaneous octreotide (100 µg) for the management of the 
carcinoid syndrome was instituted. Her symptoms improved 
dramatically over the next year. The diarrhoea abated 
completely and flushing episodes were reduced to once a 
fortnight. Over the ensuing year, regular echocardiographs 
showed minimal progression of her valvular pathology.
Discussion
Epidemiology
The true incidence of carcinoid tumours is probably 
underestimated. The annual incidence of carcinoid 
tumours, diagnosed ante mortem, is about one to two per 
100 000, according to the USA National Cancer Registry.2,3 
In comparison, the average annual incidence of carcinoid 
tumours in a large Swedish study, examining both post 
mortem and surgical specimens over 12 years, was 
8.4 per 100  000.3 Carcinoid tumours appear to have a 
bimodal age distribution, with a peak between 15-25 years, 
and another between 65-75 years of age. These tumours are 
most commonly found in the gastrointestinal tract (73.7%), 
in particular the small bowel (28.5%), appendix (18.9%) and 
rectum (11.4%), and the respiratory tract (25.1%).3 Rare 
sites include the hepatobiliary and genitourinary tracts, 
most commonly, the uterus and ovary.4 
Pathophysiology of carcinoid symptoms
The carcinoid syndrome, a constellation of symptoms 
associated with these tumours, develops in between 10-
50% of patients with carcinoid tumours.4-7 Patients with 
small bowel carcinoid tumours account for 75% of patients 
with the carcinoid syndrome.8 Carcinoid tumours produce 
various secretory products such as serotonin, histamine, 
tachykinins, kallikrein and prostaglandins. Histamine and 
kallikrein are likely mediators of pruritus and flushing, 
whereas serotonin is the most likely to induce diarrhoea.9  In 
the setting of liver metastases, or direct secretion of these 
substances into the systemic circulation (bypassing the 
portal system), these substances produce systemic effects, 
leading to the characteristic symptoms.10 The differences 
in the clinical and biochemical features relate largely to 
altered and aberrant metabolism of tryptophan. Foregut 
tumours (arising from stomach, duodenum, and bronchi) 
and ovaries frequently lack the enzyme aromatic L-amino 
acid decarboxylase (see Figure 5). Consequently, they are 
unable to produce serotonin and few symptoms occur. 
Hindgut tumours (from transverse, descending colon and 
rectum) generally lack the enzyme tryptophan hydroxylase, 
and are therefore not associated with carcinoid symptoms. 
By contrast, midgut tumours (originating from the jejunum, 
ileum, appendix and ascending colon) generally have all the 
necessary enzymes to convert tryptophan to serotonin, and 
are most likely to produce the classical carcinoid syndrome.
Diagnosis
The diagnosis is reliant on either positive histology, or 
elevated 24-hour urinary 5-HIAA levels. The latter test has a 
sensitivity of 75% and a specificity of up to 100%, provided 
that the use of certain drugs and foods are excluded.11 
Chromogranin A, by contrast, is a non-specific marker, and 
is often raised in patients with a carcinoid tumour. Depending 
on the cut-off values and assays used, its sensitivity and 
specificity are 75% and 84%, respectively.12 
Carcinoid heart disease
Patients with carcinoid syndrome have a propensity to 
develop plaque-like deposits consisting of smooth muscle, 
myofibroblasts, connective tissue and an overlying epithelial 
layer on heart valves, in particular the undersurface and 
Figure 5: Metabolism of serotonin
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chordae tendineae, and endocardium. Retraction and 
fixation of valves ensues, leading to severe deformity and 
resultant regurgitant and stenotic lesions.10,13
Pathogenesis
The right heart chambers and tricuspid and pulmonary 
valves, which receive blood directly from the liver, are 
the most commonly affected sites. However, right-sided 
lesions may also occur when the veins draining primary 
or secondary lesions bypass the portal circulation, as 
is the case with ovarian carcinoids. Left-sided cardiac 
involvement is far less common (less than 10%), as the lung 
parenchyma inactivates many of the secreted products. 
Left-sided lesions may occur with primary lung carcinoids, 
or in the presence of cardiac defects such as atrial and 
ventricular septal defects. Actual metastases to the 
myocardium account for fewer than five per cent of cardiac 
lesions associated with carcinoids.14 
While it is still debated as to whether serotonin, or another 
co-secreted hormone or by-product, is causative in the 
pathogenesis of fibrosis, evidence is mounting in favour of 
serotonin itself as the causative agent.14-18
The vast majority of serotonin (90%) originates from the 
gastrointestinal tract, predominantly from the intestinal 
enterochromaffin cells (95%), while only 10% is produced 
in the brain.17 Indirect evidence of the role of serotonin in 
the pathogenesis of valvular damage is that patients with 
cardiac involvement tend to have higher levels of urinary 
5-HIAA than those without cardiac involvement.10,15,19,20 
Drugs known to inhibit the metabolism of serotonin, e.g. 
fenfluramine and dexfenfluramine, predispose to identical 
valvular heart lesions. Additionally,  a meta-analysis of 
Parkinson’s disease treatment found that 22% (53/245) of 
patients treated with pergolide and 34% (35/102) of patients 
treated with cabergoline, both agonists of serotonin 
2B (5HT2B) receptors, had moderate-to-severe valve 
involvement, not unlike that seen in carcinoid heart disease.21 
While the exact mechanism is still unclear, Roth suggests 
that serotonin activates the G-protein-coupled 5HT2B 
receptor, leading to increased production of protein kinase 
B via activated phospholipase C. This leads to eventual 
stimulation of mitogenic pathways through activation of 
transforming growth factor beta (TGF-β), which may be 
responsible for the fibrous changes on heart valves. In a 
small study of 30 patients, over 80% of tumours produced 
TGF-β.18 Additionally, rats injected with high doses of daily 
serotonin for three months, developed increased cardiac 
mass, cardiac fibrosis and valvulopathy.22 Concomitant use 
of a serotonin receptor antagonist inhibited these changes.23 
Whether treatment with serotonin antagonists can prevent 
cardiac progression in humans is not known.
Other potential mediators of carcinoid-related fibrosis may 
involve kinins, such as tachykinins, which are known to 
stimulate DNA synthesis in fibroblasts.  Neurokinin A and 
substance P have also been linked to cardiac fibrosis.17
Clinical features and diagnosis of carcinoid heart 
disease
The lag phase between the onset of carcinoid symptoms and 
development of cardiac involvement is usually around two 
years. Often, the heralding symptoms are easy fatiguability 
and  reduced performance status. Clinical features are 
right ventricular enlargement and cardiac valve lesions, 
specifically tricuspid regurgitation and pulmonary stenosis 
and/or regurgitation. With disease progression,  patients 
develop the signs and symptoms of right heart failure.24
Echocardiography is the imaging modality of choice in 
assessing the presence and  degree of cardiac involvement. 
Typically, the valve leaflets appear thickened and have 
reduced mobility. Often the valve annulus is reduced, 
leading to stenotic lesions. The chordae tendineae become 
thickened and retracted, restricting mobility of the attached 
valve leaflets with resultant valve regurgitation.24
Natural history
Patients with carcinoid tumours progress slowly and develop 
symptoms often only 10-12 years after development of the 
primary lesion.25 Five-year survival rates from diagnosis 
depend on the site of origin, size at diagnosis, presence or 
absence of metastases, and whether the carcinoid syndrome 
coexists. Overall, survival rates range from 50-80% for 
small bowel tumours without cardiac involvement.3,26,27 The 
presence of cardiac involvement indicates a particularly 
poor prognosis, with survival rates diminishing to 
approximately 30% at five years.10,16 Symptoms of cardiac 
failure, particularly right heart failure, eventually develop in 
up to 50% of patients with carcinoid syndrome, whereas 
heart failure is present in up to 20% of patients at the time 
carcinoid syndrome is diagnosed.14,15
Therapy 
Medical therapy
Management of carcinoid tumours needs to be individualised, 
and includes medical, surgical and radioisotope therapy. 
The European Neuroendocrine Tumour Society27 published 
treatment guidelines for gastrointestinal neuroendocrine 
tumours in 2008. With respect to survival, therapies aimed at 
reducing tumour bulk and restoring normal cardiac anatomy 
have been shown to be most efficacious. However, both 
medical management, as well as radioisotope therapy, play 
an important role. Medical management includes treatment 
and control of heart failure using standard medications, 
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and symptomatic relief of carcinoid symptoms with the 
use of somatostatin analogues (octreotide). Slow-release 
formulations, albeit expensive, are available, offering 
convenient single daily dosing regimens. Symptomatic relief 
is achieved in 70% of patients on somatostatin analogue 
therapy.18 Although medical management significantly 
improves carcinoid symptoms, on its own, it does not alter 
survival. Although modest reductions in 5-HIAA levels can 
be achieved with octreotide therapy, regression of cardiac 
lesions and improved mortality has not been shown in 
studies.28 
Radioisotope therapy
Increasingly, palliation with tumour-targeted therapy, using 
Ytrium 90 or Lutetium 177m labelled Octreotide, as well 
as I131 MIBG, is being used to offer patients significant 
improvement in carcinoid symptoms. Diagnostic scans with 
Indium 111 Octreotide detect neuroendocrine tumours with 
a sensitivity of 67-100%.  I123 MIBG, traditionally used for 
detecting metastatic adrenal medullary tumours, has also 
found application in treating patients with the carcinoid 
syndrome.  Up to 70% of carcinoid tumours avidly take 
up MIBG, making I131 MIBG an attractive tumour-specific 
treatment option. SSafford et al29 published a 15-year 
retrospective review of 98 patients treated with I131 MIBG as 
palliative carcinoid treatment. Overall, the symptoms of 49% 
of patients with metastatic disease improved.  Interestingly, 
patients who experienced symptomatic improvement lived 
longer (5.76 years) compared to those whose symptoms 
were unchanged (2.09 years). A > 50% reduction in their 
urinary 5-HIAA levels was achieved in 37% of patients, and 
76% had minimal radiological evidence for reduction of 
tumour burden. 
Radiolabelled octreotide and MIBG target different 
receptors. As such, combination therapy may have a 
synergistic action.30
Surgery
The mainstay of treatment is surgery, which is aimed at 
reducing tumour bulk and improving carcinoid symptoms. 
With or without cardiac involvement, reduction in total 
tumour burden has been shown to improve survival.31,32 
These include procedures such as selective arterial 
tumour embolisation, chemoembolisation, laser-induced 
thermotherapy, radiofrequency ablation and surgical 
debulking of both primary and metastatic lesions, all of 
which have shown benefit.33 Five-year survival rates in 
patients who have surgically resectable disease (including 
liver metastases) are > 60% compared to 30% in patients 
with irresectable disease. The vast majority (over 90%) of 
patients experience symptomatic relief following surgical 
debulking.31,34 Current recommendations advise hepatic 
resection in patients where the primary tumour, locally 
advanced disease and > 90% of the hepatic tumour burden 
is deemed resectable. 
Cardiac surgery, specifically valve replacement, has 
conferred a significant survival benefit to patients with 
cardiac involvement. Since its introduction, the perioperative 
mortality has declined from 35% to nine per cent in the 
Mayo Clinic series.35 The reduction in perioperative mortality 
appeared to improve when cardiac surgery was offered to 
patients with a better baseline performance status.  Quality-
of-life and survival has improved from a mean of 11 months 
to up to four years.35 Current surgical indications in those 
with cardiac valve disease include impaired exercise 
tolerance, progressive fatigue, and worsening ventricular 
function in the presence of controlled metastatic carcinoid 
disease.
Valve replacement is preferred to valve repair, due to the 
irreversible retraction and fixation of the valve apparatus. 
The choice of prosthesis needs to be individualised. The 
inherently shortened longevity of bioprosthetic valves, 
compared with metal valves, and the incumbent need 
for anticoagulation should be considered carefully, since 
metastatic tumour deposits are at high risk of haemorrhage.24
Conclusion
Carcinoid tumours are rare malignant tumours of 
neuroendocrine origin. In addition to the typical syndrome, 
these tumours have a propensity to involve the heart in 
about 50% of patients with carcinoid syndrome. The use 
of effective serotonin antagonists has led to improvement 
in quality of life, while a proportion of patients with both 
the carcinoid syndrome and cardiac involvement have had 
survival benefit from a combination of medical therapy, 
radioisotope therapy and surgery.
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